Appl Immunohistochem Mol Morphol Journal

352 posts

Appl Immunohistochem Mol Morphol Journal banner
Appl Immunohistochem Mol Morphol Journal

Appl Immunohistochem Mol Morphol Journal

@AimmJournal

Official Journal of @ISIMMweb | Editor-in-Chief: Andrew Bellizzi @IHC_guy | Social Media Editor: Katrina Collins @katcollmd #AIMMjc #AIMMhighlights

#IHCpath Katılım Temmuz 2020
828 Takip Edilen770 Takipçiler
Appl Immunohistochem Mol Morphol Journal
🔵 CTPS1 is upregulated in CRC vs normal mucosa 🔵 High expression linked to advanced stage, metastasis, recurrence and aggressive histology 🔵 Predicts shorter PFS/DFS 🔵 Independent prognostic biomarker for CRC risk stratification
Appl Immunohistochem Mol Morphol Journal tweet media
Appl Immunohistochem Mol Morphol Journal@AimmJournal

Integrating Clinical and Molecular Insights: CTPS1 as a Key Biomarker of Tumor Progression and Prognosis in Colorectal Adenocarcinoma journals.lww.com/appliedimmunoh…

English
0
0
2
178
Appl Immunohistochem Mol Morphol Journal retweetledi
Andrew Bellizzi 🇺🇦
Andrew Bellizzi 🇺🇦@IHC_guy·
I am excited to announce our next @ISIMMweb webinar scheduled for Wednesday, Feb 18 at 11 am ET. My longtime friend and ISIMM Board member Hadi Yaziji (@MdYaziji) will present "Practical Technical Tools in Diagnostic IHC and ISH." Register here: us02web.zoom.us/webinar/regist…
Andrew Bellizzi 🇺🇦 tweet mediaAndrew Bellizzi 🇺🇦 tweet mediaAndrew Bellizzi 🇺🇦 tweet media
English
1
19
38
2.4K
Appl Immunohistochem Mol Morphol Journal
🔵 CCL8 upregulated in invasive bladder cancer 🔵 High CCL8 linked to advanced stage and nodal mets 🔵 Poor prognosis in UBUC and UTUC 🔵 Independent predictor of survival (p<0.001) 🔵 Potential biomarker for stratification
Appl Immunohistochem Mol Morphol Journal@AimmJournal

Evaluation of Clinical and Prognostic Roles of CCL8 in Urinary Bladder Cancer and Upper Tract Urothelial Carcinoma journals.lww.com/appliedimmunoh…

English
0
0
0
146
Appl Immunohistochem Mol Morphol Journal
🔵 Mesothelin in 31% pediatric and 15% adult AML; rare in ALL 🔵 ↑ in CD38⁺/CD64⁺, KMT2A-r, CBF AML (inv(16), t(8;21)) 🔵 Inverse with NPM1, GATA2, DNMT3A; ↔ CD11c, PHF6 🔵 Soluble mesothelin: 17.6% AML, 2.7% ALL; no survival/MRD impact
Appl Immunohistochem Mol Morphol Journal@AimmJournal

Mesothelin Expression in Acute Leukemia: Correlations With Immunophenotype, Cytogenetics, and Mutational Status journals.lww.com/appliedimmunoh…

English
0
0
3
374